Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab plus topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis
jRCT2031200389Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lebrikizumab in atopic dermatitis (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Investigator's Global Assessment responder rate at Week 16 and EASI-75 response at Week 16. Started Mar 2021; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031200389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200389.